The Chinese Invasive Fungal Infection Working Group published the first edition of guidelines for the diagnosis and treatment of IFD in patients with hematological disorders and cancers in 2005, and has been revised several editions thereafter. Recently, new treatments such as targeted therapy have emerged in the field of hematological cancers. These advances are modifying the definition of high-risk IFD, the epidemiology of IFD, and the strategies in IFD diagnosis and treatment. Meanwhile, diagnostic methods of IFD were evaluated in a lot of clinical studies. Therefore, the Chinese Working Group of Invasive Fungal Infections issued the latest Chinese guideline, based on Infectious Diseases Group of the European Organisation for Research and Treatment of Cancer (EORTC-IDG) and the American Mycoses Study Group (MSG) standards, the Infectious Diseases Society of America (IDSA) guidelines and the European Conference on Infections in Leukemia (ECIL) guidelines. The IFD is still classified as Proven, Probable, Possible and Undefined; the management strategies include prophylaxis, empirical antifungal therapy, diagnostic-driven antifungal therapy and targeted anti-fungal therapy. The major revisions include the epidemiology of IFD, in vitro susceptibility tests of anti-fungal drugs, and therapeutic drug concentration monitoring.